Multiple integrin ligands provide a highly adhesive and osteoinductive surface that improves selective cell retention technology. (February 2019)

• Record Type: Journal Article
• Authors: Luo, Keyu; Gao, Xiaoliang; Gao, Yuan; Li, Yan; Deng, Moyuan; Tan, Jiulin; Gou, Jing; Liu, Chuan; Dou, Ce; Li, Zhilin; Zhang, Zehua; Xu, Jianzhong; Luo, Fei
• Is Part Of: Acta biomaterialia. Volume 85(2019)
• Page Start: 106
• Page End: 116
• Publication Date: 2019-02
• Subjects: Selective cell retention -- Tissue engineering -- Cell-adhesive biomaterial -- Osteoinductive biomaterial -- Bone repair; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2018.12.018
• Languages: English
• ISSNs: 1742-7061

Abstract

Graphical abstract: Abstract: Among various bone tissue engineering strategies, selective cell retention (SCR) technology has been used as a practical clinical method for bone graft manufacturing in real time. The more mesenchymal stem cells (MSCs) are retained, the better the osteoinductive microenvironment provided by the scaffold, which in turn promotes the osteogenesis of the SCR-fabricated bone grafts. Integrin receptors are crucial to cell-matrix adhesion and signal transduction. We designed a collagen-binding domain (CBD)-containing IKVAV-cRGD peptide (CBD-IKVAV-cRGD peptide) to complement the collagen-based demineralized bone matrix (DBM) with a functionalized surface containing multiple integrin ligands, which correspond to the highly expressed integrin subtypes on MSCs. This DBM/CBD-IKVAV-cRGD composite exhibited superior in vitro adhesion capacity to cultured MSCs, as determined by oscillatory cell adhesion assay, centrifugal cell adhesion assay and mimetic SCR. Moreover, it promoted the retention of MSC-like CD271 + cells and MSC-like CD90 + /CD105 + cells in the clinical SCR method. Furthermore, the DBM/CBD-IKVAV-cRGD composite induced robust MSC osteogenesis, coupled with the activation of the downstream FAK-ERK1/2 signaling pathway of integrins. The SCR-prepared DBM/CBD-IKVAV-cRGD composite displayed superior in vivo osteogenesis, indicating that it may be potentially utilized as a biomaterial in SCR-mediated bone transplantation. Statement of Significance: Selective cell retention technology (SCR) has been utilized in clinical settings to manufacture bioactive bone grafts. Specifically, demineralized bone matrix (DBM) is a widely-used SCR clinical biomaterial but it displays poor adhesion performance and osteoinduction. Improvements of the DBM that promote cell adhesion and osteoinduction will benefit SCR-prepared implants. In this work, we developed a novel peptide that complements the DBM with a functionalized surface of multiple integrin ligands, which are corresponding to integrin subtypes available on human bone marrow-derived mesenchymal stem cells (MSCs). Our results indicate this novel functionalized bioscaffold greatly increases SCR-mediated MSC adhesion and in vivo osteogenesis. Overall, this novel material has promising SCR applications and may likely provide highly bioactive bone implants in clinical settings.